Atlas Trials

T Cell Receptor Immunotherapy Targeting MAGE-A3 for Patients With Metastatic Cancer Who Are HLA-DP0401 Positive

Clinical trial NCT02111850 · COMPLETED

Trial details

NCT number
NCT02111850
Sponsor
National Cancer Institute (NCI)
Status
COMPLETED
Phase
Phase 1, Phase 2
Study type
INTERVENTIONAL
Cervical CancerRenal CancerUrothelial CancerMelanomaBreast Cancer
Start date
2014-02-07
Primary completion
2021-03-24
Enrollment
21

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.